흡입 및 비강 스프레이 제네릭 의약품 시장 규모, 점유율 및 동향 분석 보고서 : 약품 유형별, 적응증별, 환자군별, 최종 용도별, 유통 채널별, 지역별, 부문별 예측(2025-2030년)

Inhalation And Nasal Spray Generic Drugs Market Size, Share & Trends Analysis Report By Drug Class, By Indication, By Patient Demographics, By End-use, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,612,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 10,059,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,954,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

한글목차

흡입 및 비강 스프레이 제네릭 의약품 시장 성장 및 동향

Grand View Research, Inc.의 최신 보고서에 따르면, 세계 흡입 및 비강 스프레이 제네릭 의약품 시장 규모는 2030년까지 490억 9,000만 달러에 달할 것으로 예상되며, 2025년부터 2030년까지 연평균 복합 성장률(CAGR) 8.56%를 나타낼 것으로 예상됩니다.

신제품 출시, 만성 호흡기 질환의 확산, 비용 효율적인 의약품에 대한 수요 증가, 고령 인구 증가 등이 시장 성장을 가속하는 주요 요인입니다.

비용 효율적인 의약품에 대한 수요 증가와 제네릭 의약품 사용에 대한 정부의 지원은 예측 기간 동안 흡입 및 비강 스프레이 제네릭 의약품에 대한 수요를 촉진할 것으로 예상됩니다. 예를 들어, 일본 정부는 전체 의약품 지출을 조정하기 위해 저렴한 제네릭 의약품의 사용을 장려하고 있습니다. 이는 지난 10년간 제네릭 의약품 사용을 장려하는 규제를 시행함으로써 달성되었습니다.

제약사들의 호흡기 분야 신약개발에 대한 광범위한 조사와 흡입 및 비강용 의약품의 제네릭 제품 승인은 성장을 가속할 것으로 예상됩니다. 예를 들어, 2021년 3월 Cipla Inc.는 미국 FDA로부터 편두통 치료를 위한 Imitrex Nasal Spray의 제네릭 의약품인 Sumatriptan Nasal Spray의 ANDA 승인을 획득했습니다. 또한, 2020년 5월에는 Migranal의 제네릭 의약품인 Dihydroergotamine Mesylate Nasal Spray의 ANDA 승인과 함께 FDA로부터 경쟁 제네릭 의약품(Competitive Generic Therapy) 지정을 받았습니다.

흡입 및 비강 스프레이 제네릭 의약품 시장 보고서 하이라이트

• 약물 유형별로는 기관지 확장제 부문이 2024년 29.84%의 가장 큰 매출 점유율로 시장을 주도할 것으로 예상됩니다. 세계 시장에서 기관지 확장제 부문의 성장은 천식 및 기타 호흡기 질환에 대한 즉각적인 치료에 대한 수요 증가에 의해 주도될 것으로 예상됩니다.
• 적응증별로는 천식 분야가 2024년 42.85%의 최대 매출 점유율로 시장을 주도했습니다.
• 환자군별로는 성인 환자 부문이 2024년 43.50%의 최대 매출 점유율로 시장을 주도했습니다.
• 최종 용도별로는 2024년 홈케어 부문이 55.86%의 최대 매출 점유율로 시장을 주도했습니다.
• 유통 채널별로는 소매 약국 부문이 2024년 56.96%의 최대 매출 점유율로 시장을 주도했습니다.
• 북미 흡입 및 비강 스프레이 제네릭 의약품 시장은 2024년 38.54%의 매출 점유율로 시장을 장악했습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 흡입 및 비강 스프레이 제네릭 의약품 시장 변수, 동향, 범위

• 시장 계통 전망
  • 상위 시장 전망
  • 관련/보조 시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 흡입 및 비강 스프레이 제네릭 의약품 시장 분석 툴
  • 업계 분석 - Porter의 Five Forces 분석
  • PESTEL 분석

제4장 흡입 및 비강 스프레이 제네릭 의약품 시장 : 약제 클래스 추정·동향 분석

• 부문 대시보드
• 세계의 흡입 및 비강 스프레이 제네릭 의약품 시장 : 약제 클래스 변동 분석
• 약제 클래스별, 매출
• 기관지 확장제
• 병용약
• 코르티코스테로이드
• 충혈 제거 스프레이
• 항히스타민제
• 기타

제5장 흡입 및 비강 스프레이 제네릭 의약품 시장 : 적응증 추정·동향 분석

• 부문 대시보드
• 세계의 흡입 및 비강 스프레이 제네릭 의약품 시장 : 적응증 변동 분석
• 적응증별, 매출
• 천식
• 만성 폐쇄성 폐질환(COPD)
• 알레르기성 비염
• 기타

제6장 흡입 및 비강 스프레이 제네릭 의약품 시장 : 환자 인구통계 추정·동향 분석

• 부문 대시보드
• 세계의 흡입 및 비강 스프레이 제네릭 의약품 시장 : 환자 인구 변동 분석
• 환자층별, 매출
• 성인 환자
• 소아 환자
• 고령 환자

제7장 흡입 및 비강 스프레이 제네릭 의약품 시장 : 최종 용도 추정·동향 분석

• 부문 대시보드
• 세계의 흡입 및 비강 스프레이 제네릭 의약품 시장 : 최종 용도 변동 분석
• 최종 용도별, 매출
• 홈케어
• 병원
• 기타

제8장 흡입 및 비강 스프레이 제네릭 의약품 시장 : 유통 채널 추정·동향 분석

• 부문 대시보드
• 세계의 흡입 및 비강 스프레이 제네릭 의약품 시장 : 유통 채널 변동 분석
• 유통 채널별, 매출
• 소매 약국
• 병원 약국
• 온라인 약국

제9장 흡입 및 비강 스프레이 제네릭 의약품 시장 : 제품, 용도, 최종 용도별 지역별 추정·동향 분석

• 지역 대시보드
• 시장 규모와 예측 동향 분석, 2018-2030년 :
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 노르웨이
  • 스웨덴
  • 덴마크
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 쿠웨이트

제10장 경쟁 구도

• 주요 시장 진출기업의 최근 동향과 영향 분석
• 기업/경쟁 분류
• 벤더 구도
  • 주요 기업의 시장 점유율 분석, 2024년
  • Teva Pharmaceuticals Industries Ltd
  • Viatris Inc.
  • Akorn Operating Company Llc.
  • Cipla
  • Sandoz Group Ag
  • Apotex Inc.
  • Hikma Pharmaceuticals Plc
  • Beximco Pharmaceuticals Ltd
  • Sun Pharmaceutical Industries Ltd

LSH

영문 목차

영문목차

Inhalation And Nasal Spray Generic Drugs Market Growth & Trends:

The global inhalation and nasal spray generic drugs market size is expected to reach USD 49.09 billion by 2030, registering a CAGR of 8.56% from 2025 to 2030, according to a new report by Grand View Research, Inc. New product launches, mounting prevalence of chronic respiratory diseases, growing demand for cost-effective medicines, and rising geriatric population are some of the major factors boosting the market growth.

Rising demand for cost-effective medicines and government support for the use of generics is expected to drive the demand for inhalation and nasal spray generic drugs over the forecast period. For instance, the Government of Japan has been promoting the usage of inexpensive generic drugs in order to regulate the overall pharmaceutical expenditure. This was accomplished through the execution of regulations to encourage the use of generic drugs in the past decade.

Rising number of M&A, partnerships, and collaborations among leading manufacturers including Teva Pharmaceuticals, Glenmark Specialty S.A., and Hikma Pharmaceuticals PLC is another major factor propelling the growth. For instance, in January 2022, Glenmark Specialty S.A., a Swiss subsidiary of Glenmark Pharmaceuticals Ltd., partnered with Lotus International Pte. Ltd. for marketing Ryaltris nasal spray in Vietnam, Hong Kong, and Singapore. Under this agreement, Glenmark Specialty S.A. will manufacture and supply Ryaltris, and Lotus International Pte. Ltd. will commercialize the product. Similarly, in February 2020, Glenmark Specialty signed a licensing agreement with Hikma Pharmaceuticals PLC to commercialize Ryaltrisin in the U.S.

Extensive research in the respiratory drug discovery and generic product approvals of inhalation and nasal drugs by pharmaceutical companies are projected to fuel growth. For instance, in March 2021, Cipla Inc. received ANDA approval from the U.S. FDA for Sumatriptan Nasal Spray, a generic equivalent of Imitrex Nasal Spray indicated for migraine treatment. In addition, in May 2020, the company received Competitive Generic Therapy designation from FDA along with ANDA approval for Dihydroergotamine Mesylate Nasal Spray, a generic version of Migranal.

Inhalation And Nasal Spray Generic Drugs Market Report Highlights:

• By drug class, the bronchodilators segment led the market with the largest revenue share of 29.84% in 2024. The growth of the bronchodilator drug segment in the global market is expected to be driven by the increasing demand for quick-relief treatments for asthma and other respiratory conditions
• Based on indication, the asthma segment led the market with the largest revenue share of 42.85% in 2024.
• Based on patient demographics, the adult patient segment led the market with the largest revenue share of 43.50% in 2024.
• Based on end-use, the homecare segment led the market with the largest revenue share of 55.86% in 2024.
• Based on distribution channel, the retail pharmacies segment led the market with the largest revenue share of 56.96% in 2024.
• North America inhalation and nasal spray generic drugs market dominated the inhalation and nasal spray generic drugs market with the revenue share of 38.54% in 2024.

Table Of Contents

Chapter 1. Methodology And Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Drug Class
  • 1.2.2. Indication
  • 1.2.3. Patient Demographics
  • 1.2.4. End Use
  • 1.2.5. Distribution Channel
  • 1.2.6. Regional Scope
  • 1.2.7. Estimates And Forecasts Timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. Gvr's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
  • 1.4.5. Details Of Primary Research
    • 1.4.5.1. Data For Primary Interviews In North America
    • 1.4.5.2. Data For Primary Interviews In Europe
    • 1.4.5.3. Data For Primary Interviews In Asia Pacific
    • 1.4.5.4. Data For Primary Interviews In Latin America
    • 1.4.5.5. Data For Primary Interviews In Mea
• 1.5. Information Or Data Analysis
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity Flow Analysis (Model 1)
  • 1.7.2. Approach 1: Commodity Flow Approach
  • 1.7.3. Volume Price Analysis (Model 2)
  • 1.7.4. Approach 2: Volume Price Analysis
• 1.8. List Of Secondary Sources
• 1.9. List Of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Drug Class And Indication Outlook
  • 2.2.2. Patient Demographics And End Use
  • 2.2.3. Distribution Channel Outlook
• 2.3. Competitive Insights

Chapter 3. Inhalation And Nasal Spray Generic Drugs Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Rising Incidence Of Respiratory Disease
    • 3.2.1.2. Rising Awareness About Disease
    • 3.2.1.3. Technological Advancement In Drug Development And Delivery
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Low Adoption Of Treatment In Low Middle Income Countries
    • 3.2.2.2. High Competition And Low Profit Margin
• 3.3. Inhalation And Nasal Spray Generic Drugs Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat Of New Entrant
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. Pestel Analysis
    • 3.3.2.1. Political Landscape
    • 3.3.2.2. Technological Landscape
    • 3.3.2.3. Economic Landscape

Chapter 4. Inhalation And Nasal Spray Generic Drugs Market: Drug Class Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Inhalation And Nasal Spray Generic Drugs Market: Drug Class Movement Analysis
• 4.3. Global Inhalation And Nasal Spray Generic Drugs Market Estimates And Forecasts, By Drug Class, Revenue (USD Million)
• 4.4. Bronchodilators
  • 4.4.1. Bronchodilators Market Estimates And Forecasts 2018 To 2030 (USD Million)
• 4.5. Combination Drugs
  • 4.5.1. Combination Drugs Market Estimates And Forecasts 2018 To 2030 (USD Million)
• 4.6. Corticosteroids
  • 4.6.1. Corticosteroids Market Estimates And Forecasts 2018 To 2030 (USD Million)
• 4.7. Decongestant Sprays
  • 4.7.1. Decongestant Sprays Market Estimates And Forecasts 2018 To 2030 (USD Million)
• 4.8. Antihistamines
  • 4.8.1. Antihistamines Market Estimates And Forecasts 2018 To 2030 (USD Million)
• 4.9. Others
  • 4.9.1. Others Market Estimates And Forecasts 2018 To 2030 (USD Million)

Chapter 5. Inhalation And Nasal Spray Generic Drugs Market: Indication Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Inhalation And Nasal Spray Generic Drugs Market: Indication Movement Analysis
• 5.3. Global Inhalation And Nasal Spray Generic Drugs Market Estimates And Forecasts, By Indication, Revenue (USD Million)
• 5.4. Asthma
  • 5.4.1. Asthma Market Estimates And Forecasts 2018 To 2030 (USD Million)
• 5.5. Chronic Obstructive Pulmonary Disease (Copd)
  • 5.5.1. Chronic Obstructive Pulmonary Disease (Copd) Market Estimates And Forecasts 2018 To 2030 (USD Million)
• 5.6. Allergic Rhinitis
  • 5.6.1. Allergic Rhinitis Market Estimates And Forecasts 2018 To 2030 (USD Million)
• 5.7. Others
  • 5.7.1. Others Market Estimates And Forecasts 2018 To 2030 (USD Million)

Chapter 6. Inhalation And Nasal Spray Generic Drugs Market: Patient Demographics Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global Inhalation And Nasal Spray Generic Drugs Market: Patient Demographics Movement Analysis
• 6.3. Global Inhalation And Nasal Spray Generic Drugs Market Estimates And Forecasts, By Patient Demographics, Revenue (USD Million)
• 6.4. Adult Patient
  • 6.4.1. Adult Patient Market Estimates And Forecasts 2018 To 2030 (USD Million)
• 6.5. Pediatric Patient
  • 6.5.1. Pediatric Patient Market Estimates And Forecasts 2018 To 2030 (USD Million)
• 6.6. Geriatric Patient
  • 6.6.1. Geriatric Patient Market Estimates And Forecasts 2018 To 2030 (USD Million)

Chapter 7. Inhalation And Nasal Spray Generic Drugs Market: End Use Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. Global Inhalation And Nasal Spray Generic Drugs Market: End Use Movement Analysis
• 7.3. Global Inhalation And Nasal Spray Generic Drugs Market Estimates And Forecasts, By End Use, Revenue (USD Million)
• 7.4. Homecare
  • 7.4.1. Homecare Market Estimates And Forecasts 2018 To 2030 (USD Million)
• 7.5. Hospitals
  • 7.5.1. Hospitals Market Estimates And Forecasts 2018 To 2030 (USD Million)
• 7.6. Others
  • 7.6.1. Others Market Estimates And Forecasts 2018 To 2030 (USD Million)

Chapter 8. Inhalation And Nasal Spray Generic Drugs Market: Distribution Channel Estimates & Trend Analysis

• 8.1. Segment Dashboard
• 8.2. Global Inhalation And Nasal Spray Generic Drugs Market: Distribution Channel Movement Analysis
• 8.3. Global Inhalation And Nasal Spray Generic Drugs Market Estimates And Forecasts, By Distribution Channel, Revenue (USD Million)
• 8.4. Retail Pharmacies
  • 8.4.1. Retail Pharmacies Market Estimates And Forecasts 2018 To 2030 (USD Million)
• 8.5. Hospitals Pharmacies
  • 8.5.1. Hospitals Pharmacies Market Estimates And Forecasts 2018 To 2030 (USD Million)
• 8.6. Online Pharmacies
  • 8.6.1. Online Pharmacies Market Estimates And Forecasts 2018 To 2030 (USD Million)

Chapter 9. Inhalation And Nasal Spray Generic Drugs Market: Regional Estimates & Trend Analysis By Product, Application, And End Use

• 9.1. Regional Dashboard
• 9.2. Market Size & Forecasts Trend Analysis, 2018 To 2030:
• 9.3. North America
  • 9.3.1. U.S.
    • 9.3.1.1. Key Country Dynamics
    • 9.3.1.2. Regulatory Framework/ Reimbursement Structure
    • 9.3.1.3. Competitive Scenario
    • 9.3.1.4. U.S. Market Estimates And Forecasts 2018 To 2030 (USD Million)
  • 9.3.2. Canada
    • 9.3.2.1. Key Country Dynamics
    • 9.3.2.2. Regulatory Framework/ Reimbursement Structure
    • 9.3.2.3. Competitive Scenario
    • 9.3.2.4. Canada Market Estimates And Forecasts 2018 To 2030 (USD Million)
  • 9.3.3. Mexico
    • 9.3.3.1. Key Country Dynamics
    • 9.3.3.2. Regulatory Framework/ Reimbursement Structure
    • 9.3.3.3. Competitive Scenario
    • 9.3.3.4. Mexico Market Estimates And Forecasts 2018 To 2030 (USD Million)
• 9.4. Europe
  • 9.4.1. Uk
    • 9.4.1.1. Key Country Dynamics
    • 9.4.1.2. Regulatory Framework/ Reimbursement Structure
    • 9.4.1.3. Competitive Scenario
    • 9.4.1.4. Uk Market Estimates And Forecasts 2018 To 2030 (USD Million)
  • 9.4.2. Germany
    • 9.4.2.1. Key Country Dynamics
    • 9.4.2.2. Regulatory Framework/ Reimbursement Structure
    • 9.4.2.3. Competitive Scenario
    • 9.4.2.4. Germany Market Estimates And Forecasts 2018 To 2030 (USD Million)
  • 9.4.3. France
    • 9.4.3.1. Key Country Dynamics
    • 9.4.3.2. Regulatory Framework/ Reimbursement Structure
    • 9.4.3.3. Competitive Scenario
    • 9.4.3.4. France Market Estimates And Forecasts 2018 To 2030 (USD Million)
  • 9.4.4. Italy
    • 9.4.4.1. Key Country Dynamics
    • 9.4.4.2. Regulatory Framework/ Reimbursement Structure
    • 9.4.4.3. Competitive Scenario
    • 9.4.4.4. Italy Market Estimates And Forecasts 2018 To 2030 (USD Million)
  • 9.4.5. Spain
    • 9.4.5.1. Key Country Dynamics
    • 9.4.5.2. Regulatory Framework/ Reimbursement Structure
    • 9.4.5.3. Competitive Scenario
    • 9.4.5.4. Spain Market Estimates And Forecasts 2018 To 2030 (USD Million)
  • 9.4.6. Norway
    • 9.4.6.1. Key Country Dynamics
    • 9.4.6.2. Regulatory Framework/ Reimbursement Structure
    • 9.4.6.3. Competitive Scenario
    • 9.4.6.4. Norway Market Estimates And Forecasts 2018 To 2030 (USD Million)
  • 9.4.7. Sweden
    • 9.4.7.1. Key Country Dynamics
    • 9.4.7.2. Regulatory Framework/ Reimbursement Structure
    • 9.4.7.3. Competitive Scenario
    • 9.4.7.4. Sweden Market Estimates And Forecasts 2018 To 2030 (USD Million)
  • 9.4.8. Denmark
    • 9.4.8.1. Key Country Dynamics
    • 9.4.8.2. Regulatory Framework/ Reimbursement Structure
    • 9.4.8.3. Competitive Scenario
    • 9.4.8.4. Denmark Market Estimates And Forecasts 2018 To 2030 (USD Million)
• 9.5. Asia Pacific
  • 9.5.1. Japan
    • 9.5.1.1. Key Country Dynamics
    • 9.5.1.2. Regulatory Framework/ Reimbursement Structure
    • 9.5.1.3. Competitive Scenario
    • 9.5.1.4. Japan Market Estimates And Forecasts 2018 To 2030 (USD Million)
  • 9.5.2. China
    • 9.5.2.1. Key Country Dynamics
    • 9.5.2.2. Regulatory Framework/ Reimbursement Structure
    • 9.5.2.3. Competitive Scenario
    • 9.5.2.4. China Market Estimates And Forecasts 2018 To 2030 (USD Million)
  • 9.5.3. India
    • 9.5.3.1. Key Country Dynamics
    • 9.5.3.2. Regulatory Framework/ Reimbursement Structure
    • 9.5.3.3. Competitive Scenario
    • 9.5.3.4. India Market Estimates And Forecasts 2018 To 2030 (USD Million)
  • 9.5.4. Australia
    • 9.5.4.1. Key Country Dynamics
    • 9.5.4.2. Regulatory Framework/ Reimbursement Structure
    • 9.5.4.3. Competitive Scenario
    • 9.5.4.4. Australia Market Estimates And Forecasts 2018 To 2030 (USD Million)
  • 9.5.5. South Korea
    • 9.5.5.1. Key Country Dynamics
    • 9.5.5.2. Regulatory Framework/ Reimbursement Structure
    • 9.5.5.3. Competitive Scenario
    • 9.5.5.4. South Korea Market Estimates And Forecasts 2018 To 2030 (USD Million)
  • 9.5.6. Thailand
    • 9.5.6.1. Key Country Dynamics
    • 9.5.6.2. Regulatory Framework/ Reimbursement Structure
    • 9.5.6.3. Competitive Scenario
    • 9.5.6.4. Thailand Market Estimates And Forecasts 2018 To 2030 (USD Million)
• 9.6. Latin America
  • 9.6.1. Brazil
    • 9.6.1.1. Key Country Dynamics
    • 9.6.1.2. Regulatory Framework/ Reimbursement Structure
    • 9.6.1.3. Competitive Scenario
    • 9.6.1.4. Brazil Market Estimates And Forecasts 2018 To 2030 (USD Million)
  • 9.6.2. Argentina
    • 9.6.2.1. Key Country Dynamics
    • 9.6.2.2. Regulatory Framework/ Reimbursement Structure
    • 9.6.2.3. Competitive Scenario
    • 9.6.2.4. Argentina Market Estimates And Forecasts 2018 To 2030 (USD Million)
• 9.7. Mea
  • 9.7.1. South Africa
    • 9.7.1.1. Key Country Dynamics
    • 9.7.1.2. Regulatory Framework/ Reimbursement Structure
    • 9.7.1.3. Competitive Scenario
    • 9.7.1.4. South Africa Market Estimates And Forecasts 2018 To 2030 (USD Million)
  • 9.7.2. Saudi Arabia
    • 9.7.2.1. Key Country Dynamics
    • 9.7.2.2. Regulatory Framework/ Reimbursement Structure
    • 9.7.2.3. Competitive Scenario
    • 9.7.2.4. Saudi Arabia Market Estimates And Forecasts 2018 To 2030 (USD Million)
  • 9.7.3. Uae
    • 9.7.3.1. Key Country Dynamics
    • 9.7.3.2. Regulatory Framework/ Reimbursement Structure
    • 9.7.3.3. Competitive Scenario
    • 9.7.3.4. Uae Market Estimates And Forecasts 2018 To 2030 (USD Million)
  • 9.7.4. Kuwait
    • 9.7.4.1. Key Country Dynamics
    • 9.7.4.2. Regulatory Framework/ Reimbursement Structure
    • 9.7.4.3. Competitive Scenario
    • 9.7.4.4. Kuwait Market Estimates And Forecasts 2018 To 2030 (USD Million)

Chapter 10. Competitive Landscape

• 10.1. Recent Developments & Impact Analysis, By Key Market Participants
• 10.2. Company/Competition Categorization
• 10.3. Vendor Landscape
  • 10.3.1. Key Company Market Share Analysis, 2024
  • 10.3.2. Teva Pharmaceuticals Industries Ltd
    • 10.3.2.1. Company Overview
    • 10.3.2.2. Financial Performance
    • 10.3.2.3. Product Benchmarking
    • 10.3.2.4. Strategic Initiatives
  • 10.3.3. Viatris Inc.
    • 10.3.3.1. Company Overview
    • 10.3.3.2. Financial Performance
    • 10.3.3.3. Product Benchmarking
    • 10.3.3.4. Strategic Initiatives
  • 10.3.4. Akorn Operating Company Llc.
    • 10.3.4.1. Company Overview
    • 10.3.4.2. Financial Performance
    • 10.3.4.3. Product Benchmarking
    • 10.3.4.4. Strategic Initiatives
  • 10.3.5. Cipla
    • 10.3.5.1. Company Overview
    • 10.3.5.2. Financial Performance
    • 10.3.5.3. Product Benchmarking
    • 10.3.5.4. Strategic Initiatives
  • 10.3.6. Sandoz Group Ag
    • 10.3.6.1. Company Overview
    • 10.3.6.2. Financial Performance
    • 10.3.6.3. Product Benchmarking
    • 10.3.6.4. Strategic Initiatives
  • 10.3.7. Apotex Inc.
    • 10.3.7.1. Company Overview
    • 10.3.7.2. Financial Performance
    • 10.3.7.3. Product Benchmarking
    • 10.3.7.4. Strategic Initiatives
  • 10.3.8. Hikma Pharmaceuticals Plc
    • 10.3.8.1. Company Overview
    • 10.3.8.2. Financial Performance
    • 10.3.8.3. Product Benchmarking
    • 10.3.8.4. Strategic Initiatives
  • 10.3.9. Beximco Pharmaceuticals Ltd
    • 10.3.9.1. Company Overview
    • 10.3.9.2. Financial Performance
    • 10.3.9.3. Product Benchmarking
    • 10.3.9.4. Strategic Initiatives
  • 10.3.10. Sun Pharmaceutical Industries Ltd
    • 10.3.10.1. Company Overview
    • 10.3.10.2. Financial Performance
    • 10.3.10.3. Product Benchmarking
    • 10.3.10.4. Strategic Initiatives

관련자료